Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
S-23
S-23 is one of the most potent SARMs developed, investigated as a potential male hormonal contraceptive. It showed complete suppression of spermatogenesis in animal studies while building significant lean mass.
Risk Level
High RiskDifficulty
Advanced| CAS Number | 1010396-29-8 |
| Molecular Formula | C18H13ClF4N2O3 |
| Class | SARM |
| Category | SARMs |
Mechanism of Action
S-23 is a full agonist at androgen receptors with very high binding affinity. It produces powerful anabolic effects comparable to some anabolic steroids. In rats, it completely suppressed spermatogenesis, which was reversible upon discontinuation.
Dosing Research
Animal studies used 0.1-3 mg/day in rats. Research community references 10-25 mg/day. Half-life approximately 12 hours. Cycles typically 6-8 weeks.
Side Effects & Risks
Near-complete testosterone suppression. Potential infertility during use (reversible in animal studies). Prostate enlargement observed in animal studies. Aggressive behavior reported anecdotally. No human safety data.
Research Studies
Related compounds
Ostarine
SARMOstarine is the most widely studied SARM, originally developed for muscle wasting and osteoporosis. It has completed multiple Phase II and Phase III clinical trials, making it one of the few SARMs with substantial human data.
Ligandrol
SARMLigandrol is a non-steroidal SARM developed by Ligand Pharmaceuticals for muscle wasting conditions. It demonstrated significant lean mass gains in Phase I trials at doses as low as 1 mg/day.
Cardarine
OtherCardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.
RAD-140
SARMRAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.